TerkildB Profile Banner
Terkild Brink Buus Profile
Terkild Brink Buus

@TerkildB

Followers
276
Following
3K
Media
54
Statuses
240

Assistant Professor intrigued by skin immunology and single-cell analyses at @skinUCPH.

Copenhagen
Joined June 2019
Don't wanna be here? Send us removal request.
@TerkildB
Terkild Brink Buus
1 month
Can a cancer exploit its environment and still resist treatment?.Yes, through co-existing malignant subclones!. Let me walk you through our latest study on how divergent evolution drives aggressiveness, and drug resistance of T cell cancer. 1/🧵.
Tweet media one
2
9
19
@TerkildB
Terkild Brink Buus
1 month
Finally, we would also like to thank N. Borcherding (@theHumanBorch), M. Khodadoust, A. Herrera and A. Cheng for making their data public and their gracious assistance in the annotation and elaboration of their respective single-cell RNA sequencing data sets.
1
0
0
@TerkildB
Terkild Brink Buus
1 month
RT @TerkildB: Can a cancer exploit its environment and still resist treatment?.Yes, through co-existing malignant subclones!. Let me walk y….
0
9
0
@TerkildB
Terkild Brink Buus
1 month
1
0
1
@TerkildB
Terkild Brink Buus
1 month
We greatly appreciate the constructive and professional feedback and suggestions from our reviewers and our editor @ElizSMcKenna at @CD_AACR!. We also thank @LEOFondet and the Danish Cancer Society @cancer_dk for funding the project!
1
0
1
@TerkildB
Terkild Brink Buus
1 month
This work was a team effort involving so many fantastic collaborators, clinicians, patients and their loved ones - and of course the incredible people in the group of Professor Niels Ødum. Too many people involved to list here - so go check out the paper!.
1
0
0
@TerkildB
Terkild Brink Buus
1 month
🎧 Prefer audio? We’ve generated two AI-narrated summaries of the study:. – A brief summary (~15 min) – A more in-depth version (~45 min) Great for listening on the go while diving into the details. 10/.
drive.google.com
1
0
0
@TerkildB
Terkild Brink Buus
1 month
Our findings underscore that understanding this network of specialized cancer subclones is key to overcoming treatment resistance in L-CTCL. Mapping a patient's subclonal landscape guide personalized rational combination therapies targeting all subclones for enduring response. 9/
1
0
0
@TerkildB
Terkild Brink Buus
1 month
This discovery offers an explanation for varying treatment responses across different compartments in L-CTCL patients. By targeting infections and dampening inflammation, we expose these inherent vulnerabilities, making otherwise hard-to-treat subclones susceptible to therapy. 8/
1
0
0
@TerkildB
Terkild Brink Buus
1 month
Divergent evolution results in subclones that have different tissue preferences and respond differently to external factors: cytokines and infections. The most aggressive subclones are also most sensitive to treatment if stimuli are removed exposing their vulnerabilities. 7/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
The trade-off⚖️: The subclones that respond most strongly to 🦠S. aureus toxins—the aggressive ones—are also the most intrinsically sensitive to 💊drugs when the stimuli are removed. This means reducing inflammation unmask therapeutic vulnerabilities in aggressive clones. 6/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
S. aureus infections are a major clinical problem in CTCL, fueling malignant persistence. S. aureus toxins selectively activate certain subclones, while leaving others largely unaffected. This provides a selective advantage to responsive subclones!. But it comes at a price… 5/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
These subclones show differences in tissue homing (skin/blood), metabolism, and immune signaling. Intriguingly, the subclone most abundant in blood often has less capacity for interacting with their inflammatory environment, correlating with reduced proliferation in the skin. 4/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
Using single-cell scTCR+CITE-seq on matched skin and blood, we found 🧬genetically distinct malignant subclones in more than 80% of L-CTCL patients. Subclones have distinct RNA+protein signatures, are shared between blood and skin, and co-exist over extended periods of time⏳. 3/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
TL;DR.👉Leukemic CTCL patients harbor functionally distinct co-existing subclones.👉Subclones respond differently to external factors such as infections and cancer drugs.👉The most aggressive subclones are also most sensitive to treatment if their extrinsic stimuli are removed 2/
Tweet media one
1
0
0
@TerkildB
Terkild Brink Buus
1 month
RT @ElizSMcKenna: Now online in @CD_AACR: Divergent Evolution of Malignant Subclones Maintains a Balance Between Induced Aggressiveness and….
0
12
0
@TerkildB
Terkild Brink Buus
8 months
I have moved to the other place @terkild.bsky.social - I hope to see you there!.
0
0
0
@TerkildB
Terkild Brink Buus
10 months
RT @theJIDJournal: "Breaking the Vicious Cycle of Staphylococcal aureus Skin Colonization and Progression of Cutaneous T-Cell Lymphoma," a….
Tweet card summary image
jidonline.org
We read with interest the report of Zeng et al (2024) that provides insight into the mechanism(s) whereby skin colonization by Staphylococcal aureus plays a key role in progression of cutaneous...
0
2
0
@TerkildB
Terkild Brink Buus
1 year
RT @skinucph: New @BloodJournal study by @ChellaKrishnaV and @TerkildB from Niels Ødum’s group @skinucph show bacterial infections can make….
0
3
0
@TerkildB
Terkild Brink Buus
1 year
RT @BloodJournal: Staphylococcus aureus and Sézary syndrome .#lymphoidneoplasia
Tweet media one
0
15
0